Capr stock price forecast analysts monitoring pipeline news

Analysts monitoring pipeline news expect the "capr stock price forecast" to respond sharply to any positive trial data, given the stock’s high beta behavior in the healthcare innovation space. Unlock comprehensive insights into our analysis of Capricor Therapeutics stock in this health report. Capricor Therapeutics, Inc. ( NASDAQ:CAPR - Free Report ) - Analysts at B. Riley issued their Q2 2026 earnings per share estimates for shares of Capricor Therapeutics in a note issued to investors on Sunday, September 14th. B. Riley analyst M. El-Saadi forecasts that the biotechnology company will post earnings of ($0.42) per share for the quarter. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share. B. Riley also issued estimates for Capricor Therapeutics' Q3 2026 earnings at ($0.39) EPS and Q4 2026 earnings at $2.34 EPS. Based on Q2 earnings projections, analysts see the "capr stock price forecast" testing resistance around $7.20, as institutional buying trends in small-cap biotech gain traction amid stronger R&D pipelines.